Hepatic sinusoidal obstructive syndrome (SOS), formerly known as veno-occlusive disease (VOD), is a clinical syndrome characterized by tender hepatomegaly, jaundice, ascites, fluid retention, unexplained weight gain and transfusion refractory thrombocytopenia. 1 SOS usually occurs within the first 3 weeks after high-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT).
1,2 SOS develops in 5-60% of patients after HSCT and is recognized as one of the most common and important regimen-related toxicities, given the high mortality rate. 2 The etiology of VOD remains to be fully elucidated, but is thought to involve injury to sinusoidal endothelial cells by toxic insults such as cytotoxic chemotherapy, resulting in a hypercoagulable state and exaggerated cytokine production. 3 An animal model of hepatic SOS has shown that chemotherapy causes a loss of endothelial fenestrations, the formation of gaps in the vascular lining and extravasation of red cells into the space of Disse, resulting in sinusoidal obstruction. 3 In addition, endothelial cell damage induces expression of tissue factor, which activates factor VIIa accompanied by downregulation of thrombomodulin, leading to hypercoagulation, as evidenced by deficiencies in the natural anticoagulants protein C and antithrombin (AT)III. [1] [2] [3] Recently, ATIII concentrate has been shown to be effective in the treatment of SOS after HSCT, but efficacy as a single agent remains controversial. 4 Other promising new agents for SOS include defibrotide, a mixture of singlestranded polydeoxyribonucleotides that possesses local antithrombotic, anti-ischemic and anti-inflammatory activities. 5 In multiinstitutional phase II trials involving patients with severe SOS, defibrotide produced 100-day survival rates of 35-45%, compared to 10-20% for best available therapy. 5, 6 Recombinant human soluble thrombomodulin (rTM) is composed of the active, extracellular domain of thrombomodulin, 7 and inactivates coagulation by binding to thrombin. In addition, the thrombin-rTM complex activates protein C to produce activated protein C, which in the presence of protein S inactivates factors VIIIa and Va, thereby inhibiting further thrombin formation. 8 A recent phase III trial comparing the efficacy and safety of rTM to those of low-dose heparin showed that rTM significantly improved disseminated intravascular coagulation (DIC) associated with hematological malignancies or infections. 8 Use of rTM for treatment of DIC has recently been approved in Japan.
We describe herein two cases of SOS occurring as a complication of HSCT. Both cases were successfully treated with rTM following treatment with ATIII concentrate either with or without defibrotide.
Case 1
In July 2008, a 44-year-old woman with Philadelphia chromosome-positive ALL underwent allogeneic HSCT (allo-HSCT) from a one-locus HLA-mismatched sibling donor in first hematological remission following induction chemotherapy that included imatinib. The conditioning regimen composed of fludarabine and melphalan. GVHD prophylaxis included tacrolimus and mycophenolate mofetil. On post transplant day 8, the patient developed coagulation abnormalities with fibrinogen degradation products (FDP) 15.3 mg/ml and required frequent transfusion. At that time, her body weight began to increase and she complained of tenderness in the right upper quadrant, prompting us to suspect SOS. The patient received ATIII concentrate (1500 U per day) to maintain plasma levels of ATIII above 120%. In addition, defibrotide in combination with methylprednisolone was initiated on day 9, but failed to ameliorate the right upper quadrant pain. Her weight continued to increase, reaching an 18% gain from baseline on day 12. At this time, the liver was palpable (2 cm below the right costal margin). The patient's condition deteriorated and oxygen was required. Based on the Seattle Criteria, 2 a definite diagnosis of SOS was made, although the total bilirubin was 0.6 mg/100 ml. Use of rTM (380 U/ kg per day for 6 days) was initiated on day 12, as results of coagulation tests remained above the normal ranges and indicated a state of DIC. Surprisingly, the right upper quadrant pain disappeared the day after starting rTM. Her weight promptly began to decrease and had normalized by post transplant day 30 (Figure 1 ).
Case 2
In May 2008, a 48-year-old woman was diagnosed with acute-type adult T-cell leukemia. The patient achieved CR after undergoing seven cycles of bi-weekly chemotherapy using CY, adriamycin, vincristine and prednisone. Allo-HSCT from her HLA-identical sibling was performed in October 2008. The conditioning regimen consisted of 10 Gy of TBI with high-dose (60 mg/kg) CY for 2 days. CYA and short-term MTX were used for GVHD prophylaxis. On post transplant day 7, platelet counts dropped and she required frequent transfusions. On day 9, FDP levels jumped to 45 mg/ml and ATIII concentrate (1500 U per day) was administered to keep ATIII activity above 120%. Her weight began to increase at that time, reaching a 5.8% body weight gain by post transplant day 18, when painful hepatomegaly occurred. SOS was diagnosed, although the total bilirubin was 0.8 mg/100 ml. DIC was also diagnosed, so rTM (380 U/kg per day for 9 days) was immediately initiated. The weight gain stopped and upper quadrant pain disappeared the following day. Her weight began to decrease on day 24 and had normalized within a week (Figure 1 ). PT (sec) Figure 1 Clinical course of sinusoidal obstructive syndrome (SOS). mPSL, methylprednisolone; rTM, recombinant human soluble thrombomodulin; ATIII, antithrombin III; PL, platelet transfusion.
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Neither patient displayed elevated levels of bilirubin or liver enzymes, and both patients had received ursodeoxycholic acid (UDCA) for SOS prophylaxis. A randomized study failed to show any significant reduction in SOS incidence with UDCA. However, patients who received UDCA experienced significantly fewer hepatic complications such as GVHD. 9 UDCA might have alleviated liver damage caused by SOS in the present two cases.
Engraftment syndrome is also one of the early phase complications after HSCT, and has some clinical features similar to SOS. However, neither patient developed an erythrodermatous skin rash or pulmonary edema, a feature of engraftment syndrome. In addition, their renal function was normal. Thus, it is unlikely that they had engraftment syndrome.
The ability of rTM to decrease body weight was potent. Actions as an anticoagulant alone cannot explain this potent activity. A phase III clinical trial showed that rTM increased levels of ATIII and decreased levels of plasminogen activator inhibitor 1 in patients with DIC, 8 suggesting a possible involvement of rTM in protecting endothelial cells from injury. Moreover, rTM has been shown to possess an anti-inflammatory activity through both protein-C-dependent and -independent pathways. The N-terminal domain of TM binds to and inactivates high-mobility group box 1 protein, 10 a proinflammatory cytokine that stimulates production of inflammatory cytokines such as IL-6 and tumor necrosis factor through Toll-like receptor 4 and receptor for advanced glycation end products. Thus, rTM might alleviate SOS through several different mechanisms.
Thrombomodulin is expressed on endothelial cell surfaces and is important in the anticoagulant effect on endothelium. Endothelial injury causes elevation of levels of soluble TM in plasma by proteolysis. Increased levels of soluble TM could be an early indicator of endothelial damage in SOS, although levels of soluble TM at the onset of SOS in these patients were not assessed.
Taken together, rTM appears to offer a promising new treatment strategy for patients with hepatic SOS.
